NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD
NASDAQ:BNTX (2/20/2025, 1:28:04 PM)
117.755
-1.83 (-1.53%)
The current stock price of BNTX is 117.755 USD. In the past month the price increased by 1.99%. In the past year, price increased by 27.25%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.72 | 352.72B | ||
AMGN | AMGEN INC | 14.89 | 158.49B | ||
GILD | GILEAD SCIENCES INC | 23.68 | 136.01B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1655.17 | 123.31B | ||
REGN | REGENERON PHARMACEUTICALS | 15.22 | 75.92B | ||
ARGX | ARGENX SE - ADR | N/A | 39.21B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.33B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.17B | ||
NTRA | NATERA INC | N/A | 21.94B | ||
BIIB | BIOGEN INC | 8.33 | 20.00B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.75B | ||
UTHR | UNITED THERAPEUTICS CORP | 16.4 | 16.67B |
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ 55131 DE
CEO: Ugur Sahin
Employees: 6133
Company Website: https://www.biontech.com/
Investor Relations: https://investors.biontech.de/
Phone: 4949613190840
The current stock price of BNTX is 117.755 USD. The price decreased by -1.53% in the last trading session.
The exchange symbol of BIONTECH SE-ADR is BNTX and it is listed on the Nasdaq exchange.
BNTX stock is listed on the Nasdaq exchange.
27 analysts have analysed BNTX and the average price target is 141.97 USD. This implies a price increase of 20.56% is expected in the next year compared to the current price of 117.755. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIONTECH SE-ADR (BNTX) has a market capitalization of 28.23B USD. This makes BNTX a Large Cap stock.
BIONTECH SE-ADR (BNTX) currently has 6133 employees.
BIONTECH SE-ADR (BNTX) has a support level at 119.44 and a resistance level at 121.75. Check the full technical report for a detailed analysis of BNTX support and resistance levels.
The Revenue of BIONTECH SE-ADR (BNTX) is expected to decline by -38.23% in the next year. Check the estimates tab for more information on the BNTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BNTX does not pay a dividend.
BIONTECH SE-ADR (BNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.05).
The outstanding short interest for BIONTECH SE-ADR (BNTX) is 2.99% of its float. Check the ownership tab for more information on the BNTX short interest.
ChartMill assigns a technical rating of 8 / 10 to BNTX. When comparing the yearly performance of all stocks, BNTX is one of the better performing stocks in the market, outperforming 80.76% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to BNTX. BNTX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months BNTX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS decreased by -117.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2.08% | ||
ROE | -2.44% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 79% to BNTX. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -185.35% and a revenue growth -38.23% for BNTX